Clinical-stage biopharmaceutical company Aelis Farma (Euronext Paris:AELIS) announced on Tuesday that it has been awarded EUR458,000 in non-dilutive funding under the France 2030 regional initiative in Nouvelle-Aquitaine.

This grant, allocated through the Projets d'Avenir Innovation scheme, is intended to accelerate the company's research and development efforts in obesity and related metabolic diseases.

The funding recognises the scientific merit, innovation, and value creation potential of Aelis Farma's metabolism-focused programme within a strategically important therapeutic area. The selection was conducted under a regional call for projects supported by the French State and the Nouvelle-Aquitaine Region, with operational backing from Bpifrance.

Proceeds will be directed toward advancing preclinical research, specifically the identification and characterisation of new drug candidates derived from the company's proprietary CB1-SSi platform targeting CB1 receptor signalling. This work aims to expand treatment options for obesity-related metabolic disorders and other peripheral diseases linked to CB1 receptor dysregulation.

The Nouvelle-Aquitaine component of France 2030 represents a EUR23m investment over 2025–2026, structured with matched funding from the State and the Region. Aelis Farma was selected as one of eight recipients in the latest funding round.